Navigation Links
Delpor Awarded NIH Grant for 3-month Olanzapine Implant for the Treatment of Schizophrenia
Date:2/24/2017

Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, today announced the awarding of a $224K grant from the National Institute of Mental Health (NIMH) for the further advancement of the company’s 3-month olanzapine product (DLP-119). The product is based on Delpor’s PROZOR technology and is expected to deliver therapeutic levels of olanzapine for a period of 3 months.
“We are honored and thankful to receive this award which will provide valuable resources to further advance our olanzapine implant program.” said Tassos Nicolaou, President and CEO of Delpor.

Olanzapine is one of the most widely prescribed antipsychotic drugs with sales over $4 billion before its patent expired in 2011. Long-acting antipsychotics provide substantial benefits to patients and caregivers by improving medication adherence. Currently, the only available long acting formulation of olanzapine is Zyprexa® Relprevv™, a 2-4 week depot injection. Zyprexa® Relprevv™ carries the risk of post-injection delirium/sedation syndrome (PDSS), a serious condition which includes heavy sedation, coma, and delirium after injection. Patients need to be observed for at least 3 hours post-injection in a registered facility with ready access to emergency response services, and be accompanied from the facility to their destination.

Tassos Nicolaou continued: “The lack of a 3-month olanzapine formulation, creates a tremendous unmet need within this patient population. Our goal is to move beyond the 4-week limit of the current formulation while substantially improving the safety profile of the product, including eliminating the risk of PDSS, allowing for withdrawal of the medication if needed, and delivering the medication in more favorable pharmacokinetic profile.”

About Delpor, Inc.
Delpor develops the next generation Drug Delivery Systems that improve the clinical and commercial value of drugs and biopharmaceuticals. The company’s technologies enable the sustained release of drugs through a small non-mechanical subcutaneous implant device. The device is implanted during a 10 minute, simple, in-office, procedure using local anesthetic and without the need for any surgical sutures. Delpor’s device can deliver small & large molecules within a predefined therapeutic window over several months while maintaining zero-order release pharmacokinetics. Delpor is focusing on the delivery of biologics and antipsychotics in order to improve medication adherence, safety and convenience. The company’s lead products include 3-6 month formulations of Exenatide and Risperidone. Additional information about the company can be found at http://www.delpor.com.

About DLP-119
Delpor’s DLP-119 is a matchstick-sized titanium reservoir loaded with a unique formulation of olanzapine and implanted during a simple, 10 minute, in-office procedure with local anesthesia. The product is designed to provide a constant therapeutic dose of olanzapine each day for a total period of 3 months. Additional features include reversibility, immediate onset of action, and no accumulation.

Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

Read the full story at http://www.prweb.com/releases/2017/02/prweb14088705.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device
2. Delpor Awarded $220K NIH Grant for 3-month Exenatide Implant for the Treatment of Type 2 Diabetes
3. CSO of Vortex Biosciences Dr. Elodie Sollier-Christen Awarded With 2017 SLAS Innovation Award
4. Voxeleron Awarded NIH SBIR Grant for Device-independent Retinal Image Analysis Software Platform
5. IsoPlexis Awarded NIH SBIR Grant to Develop Cellular Analysis Platform to Diagnose and Monitor Alzheimer’s
6. NanoBio Awarded U.S. Patent for RSV Vaccine
7. SRI Awarded $150 Million NIAID-DAIDS Contract to Provide Development and Manufacturing Support for Promising HIV-Prevention Products
8. Salk Institute awarded $25 million grant from Helmsley Charitable Trust
9. Lajollacooks4u Awarded TripAdvisor’s 2016 Certificate of Excellence
10. Worcester Polytechnic Institute Team Awarded Patent for Reprogramming Skin Cells
11. Noblis Awarded Army Contract for Support to the National Defense Center for Energy and the Environment (NDCEE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/15/2017)... ... June 15, 2017 , ... DuPont Industrial ... will be speaking at Bloomberg’s 2017 Sustainable Business Summit: Seattle this ... and sustainability officials on a panel titled “Developing a Corporate Renewables Strategy.” ...
(Date:6/14/2017)... ... June 14, 2017 , ... The Thailand Board ... announces that they’re co-hosting a delegation from Thailand at BIO 2017 in San ... industry gathering in the world, regroups more than 1,100 biotech companies, academic institutions, ...
(Date:6/14/2017)... ... 14, 2017 , ... Cynvenio Biosystems, Inc. a ... distribution agreements for Cynvenio’s ClearID line of blood tests that support targeted treatment selection ... ClearID available immediately in Israel, Greece, Argentina, and South Korea. , ...
(Date:6/14/2017)... ... June 14, 2017 , ... ... 1 clinical study of AC0058, a novel irreversible Bruton’s Tyrosine Kinase (BTK) ... diseases, including rheumatoid arthritis and systemic lupus erythematosus. Fifty-six (56) healthy ...
Breaking Biology Technology:
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities ... (physiological and behavioral), by technology (fingerprint, AFIS, iris recognition, ... recognition, and others), by end use industry (government and ... immigration, financial and banking, and others), and by region ... , Asia Pacific , and ...
(Date:3/27/2017)... N.Y. , March 27, 2017  Catholic ... Information and Management Systems Society (HIMSS) Analytics for ... EMR Adoption Model sm . In addition, CHS ... of U.S. hospitals using an electronic medical record ... for its high level of EMR usage in ...
Breaking Biology News(10 mins):